Highdose Ara-C/Idarubicin induction and high dose Etoposide/Cytoxan intensification in AML.

被引：0
|
作者：
Kurian, S [1 ]
Qazilbash, MH [1 ]
Lynch, JP [1 ]
Beall, CL [1 ]
Weisenborn, R [1 ]
Bunner, P [1 ]
Hobbs, G [1 ]
Auber, M [1 ]
Ericson, SG [1 ]
机构：
[1] W Virginia Univ, Bone Marrow Transplant Program, Morgantown, WV USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4641
引用
收藏
页码：213B / 213B
页数：1
相关论文
共 50 条
  • [31] Modified high dose Ara-C (mHiDAC) and daunorubicin as induction therapy for newly diagnosed AML without t(15;17).
    Lonial, S
    Langston, AA
    Bhalla, K
    Smith, KJ
    Heffner, LT
    Bucur, S
    Hutcherson, DA
    Winton, EF
    BLOOD, 1999, 94 (10) : 233B - 233B
  • [32] INTERMEDIATE-DOSE ARA-C M-AMSA FOR REMISSION INDUCTION AND HIGH-DOSE ARA-C M-AMSA FOR INTENSIVE CONSOLIDATION IN RELAPSED AND REFRACTORY ADULT ACUTE MYELOGENOUS LEUKEMIA (AML)
    JEHN, U
    HEINEMANN, V
    WILMANNS, W
    ANTICANCER RESEARCH, 1989, 9 (01) : 119 - 124
  • [33] Treatment with high dose Ara-C and Topotecan for relapsed/refractory acute myelogenous leukemia (AML).
    Case, DC
    Ebrahim, KS
    Aronson, FR
    Hedlund, JA
    BLOOD, 2000, 96 (11) : 209B - 209B
  • [34] G-CSF-priming combined with chemotherapy (idarubicin, Ara-C, VP-16) yields high remission rates in patients with advanced myelodysplastic syndromes and high-risk AML.
    Ganser, A
    Hofmann, WK
    Heil, G
    Ottmann, OG
    Fischer, JT
    Langer, W
    Herrmann, WK
    Knuth, A
    Hoffken, K
    Kolbe, K
    Schmoll, HJ
    Hertenstein, B
    Hoelzer, D
    BLOOD, 1996, 88 (10) : 834 - 834
  • [35] HIGH-DOSE ARA-C AND VP-16 WITH OR WITHOUT IDARUBICIN FOR INDUCTION OF REMISSION IN UNTREATED PRIMARY ACUTE MYELOID-LEUKEMIA
    MEHTA, J
    POWLES, R
    TRELEAVEN, J
    SINGHAL, S
    HORTON, C
    MILAN, S
    CATOVSKY, D
    BLOOD, 1994, 84 (10) : A145 - A145
  • [36] Idarubicin/Ara-C (IDAC) vs mitoxantrone/etoposide (MIET) as primary chemotherapy in a sequential induction regimen for de novo acute myeloid leukemia (AML): A randomized clinical study.
    Bernasconi, C
    Lazzarino, M
    Pagnucco, G
    Canevari, A
    Castelli, G
    Alessandrino, EP
    Brusamolino, E
    Castagnola, C
    Bernasconi, P
    Bonfichi, M
    Orlandi, E
    BLOOD, 1998, 92 (10) : 232A - 232A
  • [37] Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 "Pick a Winner" Comparison
    Burnett, Alan K.
    Hills, Robert
    Milligan, Donald
    Kell, William J.
    Wheatley, Keith
    Virchis, Andres E.
    Russell, Nigel H.
    BLOOD, 2008, 112 (11) : 1017 - 1018
  • [38] Randomized trial of idarubicin plus ARA-C +/-lisofylline in newly-disgnosed AML/MDS.
    Estey, E
    Dahlberg, S
    Kantarjian, H
    Reed, P
    Pierce, S
    MacPherson, B
    Bianco, J
    Singer, J
    Keating, M
    BLOOD, 1997, 90 (10) : 2254 - 2254
  • [39] HIGH-DOSE ARA-C RELATED LEUKOENCEPHALOPATHY
    HWANG, TL
    YUNG, WKA
    LEE, YY
    BORIT, A
    FIELDS, WS
    JOURNAL OF NEURO-ONCOLOGY, 1986, 3 (04) : 335 - 339
  • [40] Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to Idarubicin plus high dose Ara-C: A phase I study.
    Kornblau, SM
    Banker, DE
    Lemker, E
    Estrov, Z
    Faderl, S
    Verstovsek, S
    Cortes, J
    Garcia-Manero, G
    Koller, C
    Ravandi-Kashani, F
    Andreeff, M
    Jackson, CE
    Chen, WJ
    Petersdorf, S
    Estey, E
    Appelbaum, F
    BLOOD, 2005, 106 (11) : 122A - 122A
12345